Given the significantly reduced risk of hemorrhagic stroke observed in the CVOTs of SGLT2 inhibitors, it may be anticipated that SGLT2 inhibitors will reduce the risk of ICH associated with long-term antithrombotic therapy in patients with CKD. The gene discussed is SLC5A2; the disease is hemorrhagic stroke.